
British American Tobacco (BTI) Leverages 6.1% Yield to Extend Railly
Confident Investing Starts Here:
While the yield has decreased from a peak of 10% to 6.1%, primarily due to the share price rally, BTI's strong fundamentals suggest further upside potential. Here's a closer look at what continues to support the company's momentum and why I remain bullish on the tobacco giant.
Combustibles Represent Steady Cash Cow for BTI
British American Tobacco's core combustible business, which includes brands like Camel and Lucky Strike, remains a powerhouse. In this month's 2025 half-year pre-close trading update, management reported a return to growth in the U.S., a critical market, driven by stronger delivery in combustibles. Organic sales for combustibles nudged up 0.1% at constant rates, with a 5.3% price/mix improvement offsetting a 5.2% volume decline. This resilience is a remarkable achievement for a 'struggling' tobacco major, as combustibles still account for over 80% of revenue.
Despite global smoking rates dropping at a rate of mid-single digits annually, BTI's ability to raise prices and maintain margins showcases its pricing power. Additionally, CEO Tadeu Marroco highlighted cost savings of £402 million in 2024, which will help counter inflationary pressures, such as higher leaf prices, making the strong sales seem all the more impressive. Overall, with the U.S. market showing signs of stabilization, combustibles continue to fund BTI's transformation while delivering steady cash flows for dividends and buybacks.
Smokeless Growth Accelerates to BTI's Advantage
BTI's pivot to 'new categories', including vaping, heated tobacco, and oral nicotine products, is also gaining traction. The latest trading update highlighted an 8.9% organic revenue jump in these segments, with Velo Plus nicotine pouches leading the charge in the U.S. Management noted strong customer retention for Velo, which is closing the gap with Philip Morris's Zyn. Meanwhile, Glo Hilo, an upgraded heated tobacco device, is expanding into new markets, boosting competitiveness.
Though new categories contribute less than 15% of revenue compared to Philip Morris's (PM) 40%, BTI's innovation is paying off, in my view. In fact, the company raised its 2025 revenue growth guidance to 1%-2% from 1%, citing better-than-expected first-half performance in modern oral products. The CEO's confidence in achieving 3-5% revenue growth by 2026 suggests that BTI's smokeless portfolio is no longer a side hustle, or a bet, as many would argue, but a meaningful growth driver.
And while it is fair to criticize that vaping volumes dipped 9% in the first half, Vuse remains a U.S. market leader. BTI's focus on premiumization and innovation, such as synthetic nicotine in Velo Plus, positions it to capture market share in a rapidly evolving nicotine market. This segment's momentum suggests BTI is building a future beyond cigarettes.
BTI Remains a Bargain Despite Its Recent Rally
After a 57% rally, one might expect British American Tobacco (BTI) to look expensive—but it still trades at a forward P/E just under 11 while the sector median hovers at ~16, an attractive valuation even for a so-called 'sin' stock. On a trailing twelve-month basis, BTI's P/E ratio is currently 28, while the sector average is 22, indicating that although the market may view BTI as slightly overvalued today, the next twelve months appear promising.
raised its dividend for 29 consecutive years. While the yield has declined from around 10% to 6.6%, this is a result of share price appreciation, not a dividend cut. In fact, if interest rates decline as expected, BTI's dependable yield could draw even more investor interest, potentially driving the stock higher.
The company's $1 billion share buyback last year, while modest relative to its $108 billion market cap, enhances the total shareholder return. Factoring in the buyback, the blended yield rises to about 7.5%, offering even more appeal. Altogether, BTI's low valuation, strong income profile, and capital return strategy provide a compelling case for continued upside—with a margin of safety—even as the stock pushes toward new 52-week highs.
What is the Price Target for BTI?
Wall Street's stance on British American Tobacco is bearish, although with only a handful of analysts covering the stock. As things stand, BTI carries a Moderate Sell consensus based on one Sell rating in the past three months. BTI's average 12-month price target of $35.50 implies a potential downside of about 28%, suggesting that many analysts believe the stock may have already priced in much of its recent strength.
BTI Offers Yield, Value, and Further Growth Potential
Despite its 57% rally, BTI remains a strong investment option. With a 6.1% dividend yield, a valuation of less than 11x forward earnings, and solid cash flow supporting both dividends and share buybacks, BTI stands out among income-focused opportunities.
Its core combustibles business remains resilient, while growth in smokeless products, such as Velo, signals a forward-looking pivot. While regulatory headwinds and the transition to next-gen products pose challenges, BTI's global footprint and disciplined capital strategy position it well for investors seeking reliable yield and potential upside, especially in a rate-cutting environment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
3 days ago
- Business Wire
Philip Morris International to Host Webcast of 2025 Second-Quarter and First-Half Results
STAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at on Tuesday, July 22, 2025, at 9:00 a.m. ET, to discuss its 2025 second-quarter and first-half results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at The webcast recording and the slides and script will be available at The recording will be available for one year post-event. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates they were used by 38.6 million adults around the world. The smoke-free business accounted for 42% of PMI's first-quarter 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to 'PMI', 'we', 'our' and 'us' mean Philip Morris International Inc., and its subsidiaries. For more information, please visit and
Yahoo
3 days ago
- Yahoo
Philip Morris (PM) Gains on ZYN MRTP Review, Stifel Maintains Buy Rating
Philip Morris International Inc. (NYSE:PM) ranks among the . On June 13, Stifel analyst Matthew Smith maintained his Buy rating on Philip Morris International Inc. (NYSE:PM), continuing his positive outlook. The update came in response to a combination of Philip Morris's strategic posture and regulatory developments. One such development comes in the form of the FDA beginning its review of Philip Morris's Modified Risk Tobacco Product (MRTP) applications for ZYN products. This procedure, which comes after the previous PMTA approval, would give Philip Morris International Inc. (NYSE:PM) a competitive advantage in the tobacco industry by enabling it to offer ZYN with lower risk claims. Smith believes that ZYN has a good chance of being authorized under the MRTP, which is reinforced by the FDA's previous positive comments on similar products. Additionally, Philip Morris's growth profile remains robust when compared to its counterparts in the global consumer staples market, thanks to its shift to smoke-free products and smart pricing tactics. Philip Morris International Inc. (NYSE:PM) is a global tobacco company that provides services to consumers in over 180 countries. With Marlboro as its signature product, the firm stands out among the titans of 'Big Tobacco.' While we acknowledge the potential of PM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data
Yahoo
3 days ago
- Yahoo
Philip Morris International (PM): A Bull Case Theory
We came across a bullish thesis on Philip Morris International on WorldlyInvest's Substack. As of 2ⁿᵈ July, Philip Morris International's share was trading at $175.91. PM's trailing and forward P/E were 27.70 and 24.43 respectively according to Yahoo Finance. Diego Cervo/ Russo views Philip Morris International (PM) as one of the most remarkable examples in the author's portfolio of a company with the capacity to reinvest and transform itself. Over the past 14 years, PM has invested aggressively into developing Reduced Risk Products (RRPs) like IQOS, VEEV ONE, and ZYN. IQOS, its flagship heat-not-burn product, is now a major success in Japan and expanding in Western Europe. The regulatory backdrop is improving, with ZYN recently gaining FDA recognition as reduced-risk. PM's deep investments are creating network effects in its RRPs ecosystem, where scale, retail presence, and consumer loyalty drive competitive advantage. Russo sees PM as having built a durable path to grow nicotine market share in safer formats — aligning both with societal trends and future revenue/profit growth. PM's capacity to suffer — making $14B+ in RRP investments ahead of peers — positions it as the clear leader in the industry's future. The company's investments in innovation and renovation of their product lineup, underwritten cumulative smoke-free product investments of $14 billion, growing sharply from a smaller base of $2.4 billion in 2015, make it an attractive investment. Previously, we covered a on Philip Morris International by Librarian Capital in June 2025, which highlighted the company's potential as a backdoor play on the AI energy boom through its nuclear energy infrastructure assets. The stock has depreciated by 1.90% since then. This previous thesis emphasized PM's critical energy infrastructure and potential to profit from the AI energy spike, but it didn't play out as AI focus shifted. WorldlyInvest's current thesis shares a similar view on PM's growth potential, but emphasizes its successful transformation through investments in Reduced Risk Products like IQOS and ZYN, positioning it for future revenue growth. PM isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of PM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data